Irish firm Iterum Therapeutics, a clinical-stage drug developer, has joined an international consortium formed to speed up research into the discovery of new antimicrobials.
Iterum will receive €1.3 million from a total fund of €15.4m being deployed in support of seven companies in six countries by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), the Wellcome Trust announced on 25 July.
The consortium was launched a year ago with the specific goal of coming up with new classes of antimicrobial drugs that can be used to stem the emergence of superbugs.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.